0A8U Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Synlogic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.43 |
| 52 Week High | US$8.83 |
| 52 Week Low | US$1.42 |
| Beta | 1 |
| 11 Month Change | -9.82% |
| 3 Month Change | -19.48% |
| 1 Year Change | -76.75% |
| 33 Year Change | -97.66% |
| 5 Year Change | n/a |
| Change since IPO | -96.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8U | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.8% | 2.5% | -0.4% |
| 1Y | -76.7% | -23.6% | 7.7% |
Return vs Industry: 0A8U underperformed the UK Biotechs industry which returned -25.8% over the past year.
Return vs Market: 0A8U underperformed the UK Market which returned 5.8% over the past year.
Price Volatility
| 0A8U volatility | |
|---|---|
| 0A8U Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A8U's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0A8U's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Tony Awad | www.synlogictx.com |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Synlogic, Inc. Fundamentals Summary
| 0A8U fundamental statistics | |
|---|---|
| Market cap | US$17.09m |
| Earnings (TTM) | -US$73.22m |
| Revenue (TTM) | US$3.21m |
5.3x
P/S Ratio-0.2x
P/E RatioIs 0A8U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8U income statement (TTM) | |
|---|---|
| Revenue | US$3.21m |
| Cost of Revenue | US$0 |
| Gross Profit | US$3.21m |
| Other Expenses | US$76.43m |
| Earnings | -US$73.22m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.25 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,284.68% |
| Debt/Equity Ratio | 0% |
How did 0A8U perform over the long term?
See historical performance and comparison